SHCBP1 is a novel regulator of PLK1 phosphorylation and promotes prostate cancer bone metastasis

Abstract

Prostate cancer is a common male genitourinary malignancy with bone metastasis posing challenges for prognosis and treatment. This study aimed to investigate the role of SHC protein SH2 structural domain binding protein 1 (SHCBP1) in prostate cancer bone metastasis. Whole transcriptome sequencing of prostate cancer samples was conducted to identify oncogene expression, specifically focusing on SHCBP1. In vivo and in vitro models were used to study SHCBP1’s impact on bone metastasis. Through co-immunoprecipitation, mass spectrometry, and Western blot assays, the interaction between SHCBP1 and cell cycle-related proteins was elucidated, along with analysis of downstream protein partners. SHCBP1 was found to enhance prostate cancer cell development, metastasis, and mitosis, with the SHCBP1—polo-like kinase 1 (PLK1)—CDC25C axis playing a key role in promoting tumorigenesis. Therapeutic inhibition of SHCBP1 increased docetaxel sensitivity. Clinical data showed elevated SHCBP1 expression in advanced prostate cancer stages. These findings offer insights into potential therapeutic strategies for prostate cancer bone metastasis and highlight the significance of the SHCBP1-PLK1-CDC25C axis in docetaxel sensitivity.

Keywords

bone metastasis / PLK1 / prostate cancer / SHCBP1

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 3(71): 209-249.

[2] Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1, 589 patients. Hum Pathol. 2000; 5(31): 578-583.

[3] Zhang W, Bado IL, Hu J, et al. The bone microenvironment invigorates metastatic seeds for further dissemination. Cell. 2021; 9(184): 2471-2486.

[4] Kalhor R, Kalhor K, Mejia L et al. Developmental barcoding of whole mouse via homing CRISPR. Science. 2018; 6405(361).

[5] Connor AA, Denroche RE, Jang GH et al. Integration of genomic and transcriptional features in pancreatic cancer reveals increased cell cycle progression in metastases. Cancer Cell. 2019; 2(35): 267-282.

[6] Zhang Z, Li J, Ou Y et al. CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism. Signal Transduct Target Ther. 2020; 1(5): 25.

[7] Cemeli T, Guasch-Valles M, Nager M et al. Cytoplasmic cyclin D1 regulates glioblastoma dissemination. J Pathol. 2019; 4(248): 501-513.

[8] Baniwal SK, Khalid O, Gabet Y et al. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer. 2010 9: 258.

[9] Dok R, Glorieux M, Holacka K et al. Dual role for p16 in the metastasis process of HPV positive head and neck cancers. Mol Cancer. 2017; 1(16): 113.

[10] Hou PF, Jiang T, Chen F et al. KIF4A facilitates cell proliferation via induction of p21-mediated cell cycle progression and promotes metastasis in colorectal cancer. Cell Death Dis. 2018; 5(9): 477.

[11] Zhao D, Besser AH, Wander SA et al. Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation. Oncogene. 2015; 43(34): 5447-5459.

[12] Lu C, He Y, Duan J et al. Expression of Wnt3a in hepatocellular carcinoma and its effects on cell cycle and metastasis. Int J Oncol. 2017; 4(51): 1135-1145.

[13] Xia P, Zhang H, Xu K et al. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma. Cell Death Dis. 2021; 7(12): 691.

[14] Puram SV, Tirosh I, Parikh AS et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell. 2017; 7(171): 1611-1624.

[15] Iglesias-Gato D, Thysell E, Tyanova S et al. The proteome of prostate cancer bone metastasis reveals heterogeneity with prognostic implications. Clin Cancer Res. 2018; 21(24): 5433-5444.

[16] Recasens A, Munoz L. Targeting cancer cell dormancy. Trends Pharmacol Sci. 2019; 2(40): 128-141.

[17] Seki A, Coppinger JA, Jang CY et al. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science. 2008; 5883(320): 1655-1658.

[18] Montaudon E, Nikitorowicz-Buniak J, Sourd L et al. PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. Nat Commun. 2020; 1(11): 4053.

[19] Bacolod MD, Barany F. A unified transcriptional, pharmacogenomic, and gene dependency approach to decipher the biology, diagnostic markers, and therapeutic targets associated with prostate cancer metastasis. Cancers (Basel). 2021; 20(13): 5158.

[20] Reagan-Shaw S, Ahmad N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. Faseb J. 2005; 6(19): 611-613.

[21] Al NN, Cotteret S, Commo F et al. Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer. Oncotarget. 2014; 3(5): 667-678.

[22] Wang X, Yu J, Yan J et al. Single-cell sequencing reveals MYC targeting gene MAD2L1 is associated with prostate cancer bone metastasis tumor dormancy. Bmc Urol. 2022; 1(22): 37.

[23] Chakravarthi BV, Goswami MT, Pathi SS et al. MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer. Oncogene. 2016; 49(35): 6330-6340.

[24] Asano E, Hasegawa H, Hyodo T et al. The Aurora-B-mediated phosphorylation of SHCBP1 regulates cytokinetic furrow ingression. J Cell Sci. 2013; Pt 15(126): 3263-3270.

[25] Dong YD, Yuan YL, Yu HB et al. SHCBP1 is a novel target and exhibits tumor-promoting effects in gastric cancer. Oncol Rep. 2019; 3(41): 1649-1657.

[26] Liu L, Yang Y, Liu S et al. EGF-induced nuclear localization of SHCBP1 activates beta-catenin signaling and promotes cancer progression. Oncogene. 2019; 5(38): 747-764.

[27] Peng S, Chen X, Huang C et al. UBE2S as a novel ubiquitinated regulator of p16 and β-catenin to promote bone metastasis of prostate cancer. Int J Biol Sci. 2022; 8(18): 3528-3543.

[28] Kuchimaru T, Kataoka N, Nakagawa K et al. A reliable murine model of bone metastasis by injecting cancer cells through caudal arteries. Nat Commun. 2018; 1(9): 2981.

[29] Gheghiani L, Loew D, Lombard B et al. PLK1 activation in late G2 sets up commitment to mitosis. Cell Rep. 2017; 10(19): 2060-2073.

[30] Raab M, Matthess Y, Raab CA et al. A dimerization-dependent mechanism regulates enzymatic activation and nuclear entry of PLK1. Oncogene. 2022; 3(41): 372-386.

[31] Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022; 1(12): 31-46.

[32] Chen J, Lai F, Niswander L. The ubiquitin ligase mLin41 temporally promotes neural progenitor cell maintenance through FGF signaling. Genes Dev. 2012; 8(26): 803-815.

[33] Shi W, Zhang G, Ma Z et al. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer. Nat Commun. 2021; 1(12): 2812.

[34] Schmandt R, Liu SK, Mcglade CJ. Cloning and characterization of mPAL, a novel Shc SH2 domain-binding protein expressed in proliferating cells. Oncogene. 1999; 10(18): 1867-1879.

[35] Zaidi SK, Young DW, Montecino MA et al. Mitotic bookmarking of genes: a novel dimension to epigenetic control. Nat Rev Genet. 2010; 8(11): 583-589.

[36] Strauss B, Harrison A, Coelho PA et al. Cyclin B1 is essential for mitosis in mouse embryos, and its nuclear export sets the time for mitosis. J Cell Biol. 2018; 1(217): 179-193.

[37] Hiraoka D, Hosoda E, Chiba K et al. SGK phosphorylates Cdc25 and Myt1 to trigger cyclin B-Cdk1 activation at the meiotic G2/M transition. J Cell Biol. 2019; 11(218): 3597-3611.

[38] Liu K, Zheng M, Lu R et al. The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review. Cancer Cell Int. 2020; 3(20): 213.

[39] Archambault V, Lepine G, Kachaner D. Understanding the Polo kinase machine. Oncogene. 2015; 37(34): 4799-4807.

[40] Raab M, Sanhaji M, Matthess Y et al. PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells. Nat Commun. 2018; 1(9): 1106.

[41] Bruinsma W, Macurek L, Freire R et al. Bora and Aurora-A continue to activate Plk1 in mitosis. J Cell Sci. 2014; P t 4(127): 801-811.

[42] Li J, Hong MJ, Chow JP et al. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe. Oncotarget. 2015; 11(6): 9327-9340.

[43] Kang D, Chen J, Wong J et al. The checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition. J Cell Biol. 2002; 2(156): 249-259.

[44] Yin H, Zhang C, Wei Z et al. EGF-induced nuclear translocation of SHCBP1 promotes bladder cancer progression through inhibiting RACGAP1-mediated RAC1 inactivation. Cell Death Dis. 2022; 1(13): 39002E

[45] Chou CH, Loh JK, Yang MC et al. AIBp regulates mitotic entry and mitotic spindle assembly by controlling activation of both Aurora-A and Plk1. Cell Cycle. 2015; 17(14): 2764-2776.

[46] Ikeda M, Chiba S, Ohashi K et al. Furry protein promotes aurora A-mediated Polo-like kinase 1 activation. J Biol Chem. 2012; 33(287): 27670-27681.

[47] Gundem G, Van Loo P, Kremeyer B et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015; 7547(520): 353-357.

[48] Brown D, Smeets D, Szekely B et al. Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nat Commun. 2017; 8: 14944.

[49] Akhmetkaliyev A, Alibrahim N, Shafiee D et al. EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin? Mol Cancer. 2023; 1(22): 90.

[50] Vega S, Morales AV, Ocana OH et al. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 2004; 10(18): 1131-1143.

[51] Mejlvang J, Kriajevska M, Vandewalle C et al. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell. 2007; 11(18): 4615-4624.

[52] Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019; 3(29): 212-226.

[53] Bakir B, Chiarella AM, Pitarresi JR et al. EMT, MET, plasticity, and tumor metastasis. Trends Cell Biol. 2020; 10(30): 764-776.

[54] Xu N, Wu YP, Yin HB et al. SHCBP1 promotes tumor cell proliferation, migration, and invasion, and is associated with poor prostate cancer prognosis. J Cancer Res Clin Oncol. 2020; 8(146): 1953-1969.

[55] Fu Z, Wen D. The emerging role of Polo-like kinase 1 in epithelial-mesenchymal transition and tumor metastasis. Cancers (Basel). 2017; 10(9).

[56] Kim DE, Shin SB, Kim CH et al. PLK1-mediated phosphorylation of beta-catenin enhances its stability and transcriptional activity for extracellular matrix remodeling in metastatic NSCLC. Theranostics. 2023; 3(13): 1198-1216.

[57] Shin SB, Jang HR, Xu R et al. Active PLK1-driven metastasis is amplified by TGF-beta signaling that forms a positive feedback loop in non-small cell lung cancer. Oncogene. 2020; 4(39): 767-785.

[58] Lowrance WT, Murad MH, Oh WK et al. Castration-resistant prostate cancer: AUA Guideline Amendment 2018. J Urol. 2018; 6(200): 1264-1272.

[59] Mottet N, van den Bergh R, Briers E et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021; 2(79): 243-262.

[60] Cornford P, Bellmunt J, Bolla M et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017; 4(71): 630-642.

[61] Shin SB, Woo SU, Yim H. Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer. Ther Adv Med Oncol. 2019; 11: 432505881.

[62] Zhou Q, Chen X, He H et al. WD repeat domain 5 promotes chemoresistance and programmed death-ligand 1 expression in prostate cancer. Theranostics. 2021; 10(11): 4809-4824.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.